Professional Marketing briefs

AxoGen, a peripheral nerve damage devices manufacturer, hired Brad Hedger as VP, sales, a newly created position. Prior to AxoGen, Hedger directed sales and regional management positions at Synthes, before joining Stryker Orthopaedics as director of upper extremity trauma sales. He also founded and led Patient Care, prior to joining AxoGen.

Veeva Systems, a software-as-a-service company specializing in CRM programs, announced the launch of Veeva iRep, a CRM and closed-loop marketing solution built exclusively for the Apple iPad. The iRep program allows sales reps to quickly present e-detail materials, deliver interactive presentations, and show visual data and video content on the iPad, according to a statement on the launch. Marketing firm Intouch Solutions is a partner on the launch, and will provide content for iRep customers.

ReachMD, a CME and healthcare information provider, tapped Arthur Marchesini, Jr. as EVP, sales and business development. Marchesini joins ReachMD from Quintiles Medical Communications, where he was managing director of the US. Marchesini began his career in the pharmaceutical industry, spending over 10 years at Merck in various roles.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.